Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzuma...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/14/3305 |
| _version_ | 1797440466551046144 |
|---|---|
| author | Angelica Ferrando-Díez Eudald Felip Anna Pous Milana Bergamino Sirven Mireia Margelí |
| author_facet | Angelica Ferrando-Díez Eudald Felip Anna Pous Milana Bergamino Sirven Mireia Margelí |
| author_sort | Angelica Ferrando-Díez |
| collection | DOAJ |
| description | Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting. Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). In ER+ HER2+ patients, target therapies such as phosphoinositide-3-kinase (PI3K) pathway inhibition or cyclin-dependent kinases 4/6 blocking may be effective in controlling downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies. Multiple trials have explored these strategies with some promising results, and probably, in the next years conclusive results will succeed. In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents such as HER-2 therapy plus checkpoint inhibitors, or new vaccines approaches have been investigated in this setting, with promising but controversial results obtained to date. |
| first_indexed | 2024-03-09T12:07:34Z |
| format | Article |
| id | doaj.art-5111cd0718064ac3ad8ddb8b24f59187 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:07:34Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5111cd0718064ac3ad8ddb8b24f591872023-11-30T22:55:38ZengMDPI AGCancers2072-66942022-07-011414330510.3390/cancers14143305Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast CancerAngelica Ferrando-Díez0Eudald Felip1Anna Pous2Milana Bergamino Sirven3Mireia Margelí4Medical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTiP), 08916 Badalona, SpainMedical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTiP), 08916 Badalona, SpainMedical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTiP), 08916 Badalona, SpainMedical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTiP), 08916 Badalona, SpainMedical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTiP), 08916 Badalona, SpainDespite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting. Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). In ER+ HER2+ patients, target therapies such as phosphoinositide-3-kinase (PI3K) pathway inhibition or cyclin-dependent kinases 4/6 blocking may be effective in controlling downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies. Multiple trials have explored these strategies with some promising results, and probably, in the next years conclusive results will succeed. In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents such as HER-2 therapy plus checkpoint inhibitors, or new vaccines approaches have been investigated in this setting, with promising but controversial results obtained to date.https://www.mdpi.com/2072-6694/14/14/3305breast cancerHER2-positiveestrogen receptor positivetriple-positiveHER2-targeted therapyimmunotherapy |
| spellingShingle | Angelica Ferrando-Díez Eudald Felip Anna Pous Milana Bergamino Sirven Mireia Margelí Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer Cancers breast cancer HER2-positive estrogen receptor positive triple-positive HER2-targeted therapy immunotherapy |
| title | Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer |
| title_full | Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer |
| title_fullStr | Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer |
| title_full_unstemmed | Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer |
| title_short | Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer |
| title_sort | targeted therapeutic options and future perspectives for her2 positive breast cancer |
| topic | breast cancer HER2-positive estrogen receptor positive triple-positive HER2-targeted therapy immunotherapy |
| url | https://www.mdpi.com/2072-6694/14/14/3305 |
| work_keys_str_mv | AT angelicaferrandodiez targetedtherapeuticoptionsandfutureperspectivesforher2positivebreastcancer AT eudaldfelip targetedtherapeuticoptionsandfutureperspectivesforher2positivebreastcancer AT annapous targetedtherapeuticoptionsandfutureperspectivesforher2positivebreastcancer AT milanabergaminosirven targetedtherapeuticoptionsandfutureperspectivesforher2positivebreastcancer AT mireiamargeli targetedtherapeuticoptionsandfutureperspectivesforher2positivebreastcancer |